Generation Bio (GBIO) Expected to Announce Earnings on Thursday

Generation Bio (NASDAQ:GBIO) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Generation Bio to post earnings of ($2.81) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 5:00 PM ET.

Generation Bio Price Performance

NASDAQ:GBIO opened at $5.34 on Thursday. The stock has a market capitalization of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05. Generation Bio has a 52 week low of $3.00 and a 52 week high of $8.20. The firm has a 50 day moving average of $5.50 and a 200 day moving average of $5.68.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GBIO. AQR Capital Management LLC acquired a new stake in shares of Generation Bio during the first quarter worth about $36,000. Marshall Wace LLP purchased a new position in Generation Bio during the 2nd quarter worth approximately $37,000. Shay Capital LLC purchased a new position in Generation Bio during the 3rd quarter worth approximately $64,000. ADAR1 Capital Management LLC acquired a new stake in Generation Bio during the 3rd quarter valued at approximately $136,000. Finally, Torno Capital LLC purchased a new stake in shares of Generation Bio in the 4th quarter valued at $142,000. 95.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Citigroup reiterated a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Wedbush set a $5.50 price target on Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and lowered their price target for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th. Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Generation Bio in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.88.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.